Gastric ulcer disease represents a worldwide health problem because of its high morbidity and mortality. Helicobacter pylori is considered to be an important etiological factor in gastric ulcer disease and has been suggested as a cause of gastric carcinoma. Moreover, H. pylori colonizes the human gastric mucus layer and adheres to the surface epithelial cells by virtue of a variety of adhesin-like proteins. In order to effectively eradicate H. pylori infection, the therapeutic agent must be able to penetrate through the gastric mucus layer and maintain a concentration sufficient for antibacterial activity at the infected site for a suitable length of time. The most widely recommended regimen includes a triple therapy which combines various antibiotics (amoxicillin, clarithromycin, and metronidazole) and a proton pump inhibitor administered over a period of two weeks. However, the occurrence of unpleasant side effects, such as a metallic taste in the mouth, diarrhea and nausea, may cause the patient to interrupt the prescribed course of antibiotics, thus promoting the development of bacterial resistance. In our reported research (2009 Biomaterials; IF. 7.365 and 2010 Biomacromolecule; IF. 4.502), pH-responsive hydrogels and pH-sensitive nanoparticles were produced to allowing them to protect an incorporated drug from destructive gastric acids. We also demonstrated that the prepared nanoparticles can adhere to and infiltrate cell–cell junctions and cell nuclei. In the study, a platform technology in developing anti- H. pylori drug (amoxicillin and berberine) incorporated in nanoparticles composed of fucose-chitosan and heparin is proposed for eradication of targeting H. pylori. Each of the three sub-studies in this project will be designed as per the research experience and expertise obtained during this project. The targeting H. pylori nanoparticles composed of fucose-chitosan and heparin will be developed drug (amoxicillin and berberine) will be incorporated in nanoparticles, and its physicochemical characteristics, and cellular uptake nanoparticles will be analysis by confocal laser scanning microscopy (1st year). The fluorescent probe will conjugate at antibiotic and a loaded drugs nanoparticle carriers, which can suppresses the stomach H. pylori growth ability will be study. And the human gastric adenocarcinoma cell protein immunity fluorescence staining technique analysis will be established (2nd year). The study will be designed for targeting H. pylori nanoparticles studying for clinical reach. The animal living study fliorescence analysis, using IVIS 200 will be developed and the nanoparticles will be designed for targeting H. pylori studying in vivo gastric ulcer mice mode for clinical reach.
